|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||104.39 - 104.39|
|52-week range||104.39 - 104.39|
|Beta (5Y monthly)||0.79|
|PE ratio (TTM)||24.17|
|Earnings date||28 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
AbbVie Inc. (NYSE: ABBV) recently cratered, as modest yearly gains almost got wiped out in a single session. Meanwhile, downward pressure continues as the price looks to test the support around US$100 for the third time this year. We will examine the dividend as the stock dips down below the P/E of 30 since a 4.8% yield is certainly interesting at the right price.
COPENHAGEN, Denmark & NORTH CHICAGO, Ill., September 09, 2021--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced The Lancet published the results of the dose escalation part of the phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL). The full manuscript is a
Does the September share price for AbbVie Inc. ( NYSE:ABBV ) reflect what it's really worth? Today, we will estimate...